Kaja Kostyrko

Vienna, 1120, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR-mutant lung cancer.

SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR-mutant lung cancer.

Journal: Science signaling

Published: November 25, 2025

SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD.

SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 12, 2025

Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response.

Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response.

Journal: Cancer research communications

Published: April 07, 2024

SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma.

SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma.

Journal: bioRxiv : the preprint server for biology

Published: December 18, 2023

SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.

SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.

Journal: Cancer research

Published: October 17, 2023

Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance.

Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance.

Journal: bioRxiv : the preprint server for biology

Published: February 07, 2023

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.

Journal: Nature cancer

Published: January 23, 2023

UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma.

UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma.

Journal: Nature communications

Published: May 27, 2022

An Expanded Tool Kit for Modeling the Oncogenic Functions of KRAS.

An Expanded Tool Kit for Modeling the Oncogenic Functions of KRAS.

Journal: Cancer discovery

Published: November 03, 2020

Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities.

Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities.

Journal: Cancer discovery

Published: November 04, 2019

CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities.

CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities.

Journal: Nature

Published: April 25, 2019

The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas.

The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas.

Journal: The Journal of clinical investigation

Published: March 21, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026